RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
772. Quaschning T, Schömig M, Wanner C, Thiery J, Nauck M,
Schollmeyer P y cols. Non insulin dependent diabetes mellitus
and hypertriglyceridemia impair lisoprotein metabolism
in chronic hemodialysis patients. J Am Soc Nephrol 10: 332-
341, 1999
773. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The
hyperlipidemia of the nephrotic syndrome. Relation to plasma
albumin concentration, oncotic pressure, and viscosity.
N Engl J Med 312: 1544-1548, 1985.
774. Ordóñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased
risk of coronary artery disease associated wiyh nephrotic
syndrome. Kidney Int 44: 638-642, 1993
775. De Sain-van der Velden MG, Kaysen GA, Barrett HA,
Stellaard F, Gadellaa MM, Voorbij HA y cols. Increased
VLDL in nephrotic patients results from a decreased catabolism
while increased LDL results from increased synthesis.
Kidney Int 53: 994-1001, 1998
776. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic
syndrome, lipids, and risk factors for cardiovascular disease.
Am J Kidney Dis 22: 135-142, 1993
777. Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia
and Thrombotic complications in patients with membranous
nephropathy. Seminars in Nephrology 23: 406-411, 2003
778. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A,
Lang U y cols. Multicenter study of lipoprotein(a) and apolipoprotein(a)
phenotypes in patients with end-stage renal
disease treated by hemodialysis or continous ambulatory
peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
779. Covic A, Gusbeth-Tatomir P, Goldsmith D. The challenge of
cardiovascular risk factors in end stage renal disease. J
Nephrol 16: 476-486, 2003
780. Prichard S. Impact of dyslipidemia in end stage renal disease.
J Am Soc Nephrol 14: S315-S320, 2003
781. Horkko S, Huttunen K, Kesaniemi YA. Decreased clearance
of low density lipoprotein in uremic patients under dialysis
treatment. Kidney Int 47: 1732-1740, 1995
782. Pedro-Botet J, Senti M, Rubies Prat J, Pelegri A, Romero R.
When to treat dyslipidaemia of patients with chronic renal
failure on haemodialysis? A need to define specific guidelines.
Nephrol Dial Transplant 11: 308-313, 1996
783. Hernández E, Praga M, Alamo C, Araque A, Morales JM,
Ruilope LM, Rodicio JL. Lipoprotein(a) and vascular access
survival in patients on chronic hemodialysis. Nephron 72:
145-149, 1996
784. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K,
Tabata T Seccia M, Bellomo G. Atherogenic lipoprotein
changes in the absence of hyperlipidemia in patients with
renal failure treated by hemodialysis. Atherosclerosis 131:
229-236, 1997
785. Maggi E, Bellazzi R, Gazo A, y cols. Autoantibodioes against
oxidatively modified LDL in uremic patients undergoing
dialysis. Kidney Int 46: 869-876, 1994
786. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM,
Packard CJ. Atherogenic lipoprotein phenotype in end stage
renal failure. Origin and extent of small dense low density
lipoprotein formation. Am J kidney Dis 35: 852-862, 2000
787. Ramos R, Gómez Gerique N, Martínez Castelao A, Estrés
oxidativo de las lipoproteínas y efecto antioxidante de la
vitamina C un año después de iniciar hemodiálisis.
Nefrología 2004, en prensa.
788. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, Konig P,
Auinger M y cols. Prevalence of dyslipidemic risk factors in
hemodialysis and CAPD patients. Kidney Int 63 (suppl 84):
S113-S116, 2003
789. Harris K, Thomas M, Short C, Moore R. Assesment of the efficiency
of treatment of dyslipidaemia in renal outpatients. J
Nephrol 15: 263-269, 2002
790. Attman PO, Samuelsson O, Moberly J, Johansson AC,
Ljungman S, Weiss LG y cols. Apolipoprotein B containing
lipoproteins in renal failure. The relation to mode of dialysis.
Kidney Int 1536-1542, 1999
791. Moberly JB, Attman PO, Samuelsson O, Johansson AC,
Knight-Gibson C, Alaupovic P. Alterations in lipoprotein
composition in peritoneal diálisis patients. Periton Dialysis
Int 22:1-9, 2002
792. Wheeler DC. Abnormalities of lipoprotein metabolism in
CAPD patients. Kidney Int 50 (suppl 56): S41-S46, 1996
793. Johansson AC, Samuelsson O, Attman PO, Haraldsson B,
Moberly J, Knight-Gibson C y cols. Dyslipidemia in peritoneal
diálisis relation to dialytic variables. Periton Dialysis Int
20: 306-314, 2000
794. Llopart R, Donate T, Oliva JA, Roda M, Rousaud F,
Gonzalez-Sastre F y cols. Trigyceride rich lipoprotein abnormalities
in CAPD treated patients. Nephrol Dial Transplant
10: 537-540, 1995
795. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van
Leusen R. Effects of peritoneal dialysis with an overnight
icodextrin dwell on parameters of glucose and lipid metabolism.
Periton Dialysis Int 21: 275-281, 2001.
796. Castelao AM, Barbera MJ, Blanco A, Fiol C, Grino JM, Bover
J, y cols. Lipid metabolic abnormalities after renal transplantation
under cyclosporine and prednisone immunosuppression.
Transplant Proc 24: 96-98, 1992.
797. Gonyea JE, Anderson CF. Weight change and serum lipoproteins
in recipients of renal allografts. Mayo Clinic Proc 67:
653-657, 1992
798. Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal
transplant patients. J Intern Med 239: 407-415, 1996
799. Brown JH, Murphy BG, Douglas AF, Short CD, Bhatnagar D,
Mackness MI y cols. Influence of immunosuppressive therapy
on lipoprotein(a) and others lipoproteins following
renal transplantation. Nephron 75: 277-282, 1997
800. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ
transplantation. Transplantation 63: 331-338, 1997
801. Marcen R, Pascual J. Enfermedades cardiovasculares en el
trasplante renal. Nefrología 21: 104-114, 2001.
802. Hricik DE, Mayes JT, Schulak JA. Independent effects of
cyclosporine and prednisone on posttransplant hypercholesterolemia.
Am J Kidney Dis 18: 353-358, 1991
803. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA.
Cardiovascular risk factors in renal transplant patients:
cyclosporin A versus tacrolimus. J Am Soc Nephrol 12: 368-
373, 2001
804. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in
end stage renal disease patients. Am J Kidney Dis 38 (4 suppl
1): S26-S29, 2001
805. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR,
Hachey DL, Jaffe JS y cols. Effect of sirolimus on the metabolism
of ApoB100 containing lipoproteins in renal transplant
patients. Transplantation 72: 1244-1250, 2001
211